Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

At first, Chinese pharmaceutical companies rushed to make similar versions of blockbuster weight-loss drugs, such as Wegovy and Ozempic ... such as sleep apnoea, fatty liver disease, chronic kidney ...

Novo Nordisk launches Wegovy in India, a once-weekly weight-loss injection shown to aid obesity treatment and reduce heart ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Novo Nordisk has introduced Wegovy, a once-weekly weight loss injection, in India. The drug aims to manage obesity and reduce ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

Novo Nordisk is planning a major India launch of its blockbuster weight-loss drug Wegovy, aiming for Rs 8,600 crore in sales within 5–7 years. The company eyes top spot in prescription drug sales with ...

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.

Altimmune shares cratered nearly 60% on Thursday after its experimental obesity drug did not significantly improve liver ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...